Holen Sie sich die Stockscreener-App
0.7959
0.03%
-0.0002
Handel nachbörslich:
.79
-0.0059
-0.74%
Schlusskurs vom Vortag:
$0.7961
Offen:
$0.81
24-Stunden-Volumen:
469.35K
Relative Volume:
0.52
Marktkapitalisierung:
$89.45M
Einnahmen:
$3.17M
Nettoeinkommen (Verlust:
$-36.23M
KGV:
-1.9469
EPS:
-0.4088
Netto-Cashflow:
$-17.11M
1W Leistung:
+2.45%
1M Leistung:
+14.14%
6M Leistung:
-37.82%
1J Leistung:
+44.71%
1-Tages-Spanne:
$0.7751
$0.816
1-Wochen-Bereich:
$0.7701
$0.8238
52-Wochen-Spanne:
$0.4404
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Firmenname
Rani Therapeutics Holdings Inc
Sektor
Branche
Telefon
(408) 457-3700
Adresse
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.7959 | 89.47M | 3.17M | -36.23M | -17.11M | -0.4088 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Lake Street | Buy |
| 2024-08-02 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-14 | Eingeleitet | Maxim Group | Buy |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-07-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Rani Therapeutics Holdings Inc Aktie (RANI) Neueste Nachrichten
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline - MarketBeat
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
RA Capital details 11,530,414 Rani Therapeutics (RANI) shares under 9.99% cap - Stock Titan
Rani Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates - Investing.com Canada
8-K: Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Updatemoomoo - Moomoo
Rani Therapeutics (NASDAQ:RANI) Announces Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Rani Therapeutics Q2 Results: EPS beats estimate, sales up 85% - scanx.trade
Rani Therapeutics (RANI) boosts liquidity with $20M raise and Chugai revenue - Stock Titan
Rani Therapeutics reports Q2 2026: $1.7M contract revenue, $8.4M quarterly net loss, $53.4M cash - TradingView
Rani Therapeutics' Oral RT-114 Tops 150% Bioavailability - Stock Titan
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update - GlobeNewswire
Rani Therapeutics at Canaccord Genuity conference: oral biologics push By Investing.com - Investing.com Canada
RANI: Oral biologics platform shows strong clinical and business momentum, with funding secured into 2027 - TradingView
Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Rani Therapeutics CEO, CFO to Present, Hold 1x1 Meetings Aug. 12 - Stock Titan
IMDX Stock Price and Chart — NASDAQ:IMDX - TradingView
Rani Therapeutics Holdings Inc (RANI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RANI Q2'26 Earnings: EPS estimate is (0.05) USD - TradingView
Rani Therapeutics appoints Michelle Gilson to board By Investing.com - Investing.com UK
Rani Therapeutics Holdings, Inc. (RANI) awards 247,200 stock options to director - Stock Titan
Rani Therapeutics Holdings, Inc. (RANI) details director option holding - Stock Titan
Rani Therapeutics files Form 3 for director Michelle Gilson - Bitget
Rani Therapeutics appoints Michelle Gilson to board - Investing.com
Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair - Quiver Quantitative
Rani Therapeutics appoints Michelle Gilson to board and as Audit Committee chair - TradingView
Rani Therapeutics Appoints Michelle Gilson to Board of Directors - Yahoo Finance
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Enterprise value to EBITDA forward of Rani Therapeutics Holdings, Inc. – NASDAQ:RANI - tradingview.com
Vanguard Capital Management discloses 5,052,862 Rani Therapeutics (RANI) shares in ownership report - Stock Titan
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Rani Therapeutics (NASDAQ:RANI) CEO Buys 35,000 Shares - MarketBeat
Rani Therapeutics Holdings Inc (RANI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rani Therapeutics Holdings Inc - TradingKey
Rani Therapeutics Holdings Inc (RANI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rani Therapeutics Holdings Inc (RANI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RANI|Rani Therapeutics Holdings Inc|Price:0.810|Chg%:-0.000 - TradingKey
Rani Therapeutics Holdings Inc (RANI) Institutional Confidence - TradingKey
RANI|Rani Therapeutics Holdings Inc|Price:0.805|Chg%:+0.007 - TradingKey
Rani Therapeutics Hldgs Market Sentiment - Benzinga España
RANI|Rani Therapeutics Holdings Inc|Price:0.801|Chg%:-0.009 - TradingKey
TradingKey - TradingKey
Rani Therapeutics Holdings Inc (RANI) Cash Flow - TradingKey
Rani Therapeutics Holdings Inc (RANI) Balance Sheet - TradingKey
Rani Therapeutics director Mir A Imran buys $24,839 in stock - Investing.com UK
Form 4 Rani Therapeutics Holdings Inc For: 24 July By Investing.com - Investing.com South Africa
Rani Therapeutics director Mir A Imran buys $24,839 in stock By Investing.com - Investing.com Nigeria
Rani Therapeutics Holdings Inc. (RANI) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director IMRAN MIR A - Moomoo
Rani Therapeutics (RANI) insider Imran Mir A buys 36,000 shares - Stock Titan
Rani Therapeutics Holdings (NASDAQ:RANI) surges 29%, shrinking Nasdaq compliance deficit to 11% - TechStock²
Finanzdaten der Rani Therapeutics Holdings Inc-Aktie (RANI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rani Therapeutics Holdings Inc-Aktie (RANI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Javadi Alireza | Chief Technical Officer |
Mar 27 '26 |
Sale |
0.78 |
386 |
301 |
9,689 |
| Imran Talat | Chief Executive Officer |
Jul 17 '26 |
Buy |
0.72 |
35,000 |
25,193 |
469,736 |
| IMRAN MIR A | Director |
Oct 23 '25 |
Buy |
0.60 |
2,083,334 |
1,260,417 |
2,083,334 |
| South Cone Investments Limited | 10% Owner |
Oct 21 '25 |
Sale |
2.77 |
4,000,000 |
11,074,000 |
2,379,194 |
| South Cone Investments Limited | 10% Owner |
Oct 20 '25 |
Sale |
2.41 |
1,923,000 |
4,637,314 |
6,379,194 |
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):